A translational research lab @mskcancercenter.bsky.social focused on the immunobiology and therapeutic potential of genetically engineered #Tcells and #TCRs. Est. 2016 @NYC
Klebanoff Lab
Loading...
🚨Today in @cp-cancercell.bsky.social:
50,000 tumor genomes via MSK-IMPACT. We map which HLA alleles are highest yield for antigen discovery—and define when HLA LOH constrains targetability.
A framework for scaling TCR therapies.
@mskcancercenter.bsky.social
authors.elsevier.com/sd/article/S...
🚨This week in @natcomms.nature.com: We resolve an enduring enigma in T cell biology—how TCR binding to p/HLA triggers intracellular signaling. CryoEM in native environment reveals a 'jack-in-the-box' mechanism! Collab btw
@rockefeller.edu @mskcancercenter.bsky.social
rdcu.be/eUPPl
Complete tumor eradication with cell therapies depends on persistence of donor CAR-cells in the patient
@klebanofflab.bsky.social show that deletion of Fas on donor CAR-T/CAR-NK improves persistence in FasL-dependent (host NK & T) manner @natcancer.nature.com
www.nature.com/articles/s43...
🚨Today, in #NatureCancer, we show that #CAR-T cells and #CAR-NK cells contain the seeds of their own self-destruction. Disruption of a FAS-L/FAS enhances CAR potency against liquid and solid cancers. rdcu.be/exjEy. @mskcancercenter.bsky.social @parkerici.bsky.social
Excited to announce a new paper in @aacrjournals.bsky.social with Junwei Shi and Tony Daniyan. We perform screens of GAPs and GEFs in AML and discover a hematopoietic-specific GAP (ARHGAP45) required in a variety of hematologic malignancies:
aacrjournals.org/cancerdiscov...
Klebanoff Lab
Register for the 2026 Spring Scientific! This program will feature in-depth explorations and discussions of recent scientific breakthroughs, cutting-edge technologies, and the newest clinical studies. View the full list of faculty and sessions: www.sitcancer.org/spring-scientific-schedule-2026
Nature Communications - The T-cell receptor (TCR) activation mechanism has remained uncertain. Here, the authors present molecular structures for the apo and ligand-bound human TCR–CD3...
Latest preprint from the team: micropolymorphisms in HLAs tune peptide conformational ensembles, altering structural adaptability & contributing to TCR specificity. Even if static structures & pep affinites are the same, closely related HLAs may not be.
#immunosky
www.biorxiv.org/content/10.6...
📢New Article published at Nature Cancer!
✒️By Christopher Klebanoff and colleagues
'CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit'
🔗 www.nature.com/articles/s43...
MSK’s @klebanofflab.bsky.social and team found that FAS ligand, which hampers #CAR-T and #CAR-NK therapies, is actually produced by immune cells themselves.
Klebanoff Lab
MSK physician-scientist Dr. Christopher Klebanoff talked about all things #neoantigens for the Novel Classes of Human Cancer Rejection Antigens session this morning at #AACR25.
Waggoner Lab
Klebanoff Lab
Nature Cancer - Klebanoff and colleagues report that survival and persistence of CAR-T and CAR-NK cells are regulated by a FAS ligand–FAS autoregulatory circuit, showing that disabling FAS...
T cell receptor (TCR) restriction by highly polymorphic major histocompatibility complex (MHC) proteins is a foundation of cellular immunity. Although the effects of MHC polymorphisms on peptide bindi...
Klebanoff and colleagues report that survival and persistence of CAR-T and CAR-NK cells are regulated by a FAS ligand–FAS autoregulatory circuit, showing that disabling FAS signaling enhances their an...
